Amy D Shapiro

Summary

Affiliation: Indiana Hemophilia and Thrombosis Center
Country: USA

Publications

  1. ncbi U.S. survey of surgical capabilities and experience with surgical procedures in patients with congenital haemophilia with inhibitors
    A Shapiro
    Indiana Hemophilia and Thrombosis Center, Indianapolis, IN 46260, USA
    Haemophilia 18:400-5. 2012
  2. ncbi Knowledge and therapeutic gaps: a public health problem in the rare coagulation disorders population
    Amy D Shapiro
    Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana 46260, USA
    Am J Prev Med 41:S324-31. 2011
  3. ncbi Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients
    Amy D Shapiro
    Indiana Hemophilia and Thrombosis Center, Indianapolis, 46260, USA
    Blood 119:666-72. 2012
  4. ncbi Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A
    Amy Shapiro
    Indiana Hemophilia and Thrombosis Center, 8402 Harcourt Rd, Suite 420, Indianapolis, IN 46260, USA
    Expert Opin Biol Ther 9:273-83. 2009
  5. ncbi Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors
    Amy D Shapiro
    Indiana Hemophilia and Thrombosis Center, Indianapolis, IN 46260, USA
    Clin Adv Hematol Oncol 6:579-86. 2008
  6. ncbi Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A
    Amy D Shapiro
    Indiana Hemophilia and Thrombosis Center, 8402 Harcourt Rd, Suite 420, Indianapolis, IN 46260 USA
    Vasc Health Risk Manag 3:555-65. 2007
  7. ncbi Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study
    A D Shapiro
    Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana 46260, USA
    Pediatrics 108:E105. 2001
  8. ncbi A global view on prophylaxis: possibilities and consequences
    A D Shapiro
    Indiana Hemophilia and Thrombosis Center, Indianapolis 46260, USA
    Haemophilia 9:10-7; discussion 18. 2003
  9. ncbi Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia
    A D Shapiro
    Indiana Hemophilia and Thrombosis Center, Inc, Indianapolis, IN 46260, USA
    Haemophilia 11:571-82. 2005
  10. ncbi The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B
    Amy D Shapiro
    Indiana Hemophilia and Thrombosis Center, Indianapolis 46260, USA
    Blood 105:518-25. 2005

Detail Information

Publications18

  1. ncbi U.S. survey of surgical capabilities and experience with surgical procedures in patients with congenital haemophilia with inhibitors
    A Shapiro
    Indiana Hemophilia and Thrombosis Center, Indianapolis, IN 46260, USA
    Haemophilia 18:400-5. 2012
    ..Identification of best practices and surgical barriers is required to guide future initiatives to support these patients...
  2. ncbi Knowledge and therapeutic gaps: a public health problem in the rare coagulation disorders population
    Amy D Shapiro
    Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana 46260, USA
    Am J Prev Med 41:S324-31. 2011
    ..We believe that this model is effective and adaptable to other rare conditions...
  3. ncbi Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients
    Amy D Shapiro
    Indiana Hemophilia and Thrombosis Center, Indianapolis, 46260, USA
    Blood 119:666-72. 2012
    ..These results show that rFIXFc may offer a viable therapeutic approach to achieve prolonged hemostatic protection and less frequent dosing in patients with hemophilia B. The trial was registered at www.clinicaltrials.gov as NCT00716716...
  4. ncbi Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A
    Amy Shapiro
    Indiana Hemophilia and Thrombosis Center, 8402 Harcourt Rd, Suite 420, Indianapolis, IN 46260, USA
    Expert Opin Biol Ther 9:273-83. 2009
    ....
  5. ncbi Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors
    Amy D Shapiro
    Indiana Hemophilia and Thrombosis Center, Indianapolis, IN 46260, USA
    Clin Adv Hematol Oncol 6:579-86. 2008
    ..The single-dose 270 microg/kg rFVIIa regimen utilized similar product consumption to the 3 x 90 microg/kg rFVIIa treatment regimen...
  6. ncbi Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A
    Amy D Shapiro
    Indiana Hemophilia and Thrombosis Center, 8402 Harcourt Rd, Suite 420, Indianapolis, IN 46260 USA
    Vasc Health Risk Manag 3:555-65. 2007
    ..Experience with ADVATE, and its place in today's treatment paradigm, is the focus of this article...
  7. ncbi Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study
    A D Shapiro
    Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana 46260, USA
    Pediatrics 108:E105. 2001
    ..Finally, we explored the mechanisms for the association between bleeding episodes and academic achievement...
  8. ncbi A global view on prophylaxis: possibilities and consequences
    A D Shapiro
    Indiana Hemophilia and Thrombosis Center, Indianapolis 46260, USA
    Haemophilia 9:10-7; discussion 18. 2003
    ....
  9. ncbi Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia
    A D Shapiro
    Indiana Hemophilia and Thrombosis Center, Inc, Indianapolis, IN 46260, USA
    Haemophilia 11:571-82. 2005
    ..We highlight the importance of considering an individual pharmacokinetic study in all patients starting a new coagulation product...
  10. ncbi The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B
    Amy D Shapiro
    Indiana Hemophilia and Thrombosis Center, Indianapolis 46260, USA
    Blood 105:518-25. 2005
    ..rFIX was well tolerated, with no associated thrombotic events or evidence of viral transmission. These data indicate that rFIX is a safe and effective treatment for PUPs with hemophilia B...
  11. ncbi Why is primary prophylaxis underutilized in the United States?
    A D Shapiro
    Indiana Hemophilia and Thrombosis Center, Indianapolis, IN 46260, USA
    Haemophilia 9:670-2. 2003
    ..This article discusses the issues that may contribute to utilization of prophylactic regimens and issues to consider when determining treatment programs for pediatric patients...
  12. ncbi Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry
    R Parameswaran
    Indiana Hemophilia and Thrombosis Center, IN, USA
    Haemophilia 11:100-6. 2005
    ..Recombinant FVIIa appears to have a wide safety margin that may allow dose escalation to address these questions...
  13. ncbi VERITAS-PRN: a new measure of adherence to episodic treatment regimens in haemophilia
    N A Duncan
    Indiana Hemophilia and Thrombosis Center, 8402 Harcourt Rd, Indianapolis, IN 46260, USA
    Haemophilia 16:47-53. 2010
    ..This tool may be utilized as a standard measure of adherence to increase sensitivity to adherence problems and promote targeted interventions to enhance adherence and health outcomes...
  14. ncbi An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents
    R Mehta
    Department of Clinical Medicine, Section of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN, USA
    Haemophilia 12:54-61. 2006
    ..The historical use, clinical practice concerns, published comparative studies and methods for optimization of these two bypassing agents are reviewed...
  15. ncbi Plasminogen activator inhibitor type 1 deficiency
    R Mehta
    Department of Clinical Medicine, Section of Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Haemophilia 14:1255-60. 2008
    ..Because of lack of standardized commercially available PAI-1 activity assay sensitive in the lowest range, the true prevalence of this rare condition has not been established...
  16. ncbi Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B
    Bruce M Ewenstein
    Hematology Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Transfusion 42:190-7. 2002
    ..Hemophilia B is an X-linked bleeding disorder that affects approximately 1 in 25,000 males. Therapy for acute bleeding episodes consists of transfusions of plasma-derived (pd-F IX) or recombinant (r-F IX) concentrates...
  17. ncbi Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
    Marilyn J Manco-Johnson
    University of Colorado and Health Sciences Center, Denver, USA
    N Engl J Med 357:535-44. 2007
    ..Effective ways to prevent arthropathy in severe hemophilia are unknown...
  18. ncbi Central venous access device infections in children with hemophilia: a comparison of prophylaxis and episodic therapy
    Michele R Hacker
    Mountain States Regional Hemophilia and Thrombosis Center, University of Colorado, Denver, USA
    J Pediatr Hematol Oncol 29:458-64. 2007
    ..Given the need for CVADs in some children and the benefits of prophylaxis, we conclude there is no reason to recommend against prophylaxis on the basis of existing knowledge of CVAD-related infection risk...